From: Cancer immunotherapies targeting the PD-1 signaling pathway
PD-1/PD-L1mAb | Combination | Tumor | Reference |
---|---|---|---|
PD-1 mAb (Nivolumab) | LAG3 (BMS-986016) | Solid Tumors | NCT01968109 |
PD-1 mAb (Nivolumab) | B7-H3 (Enoblituzumab) | Solid Tumors | NCT02817633 |
PD-1 mAb (Pembrolizumab) | B7-H3 (Enoblituzumab) | Solid Tumors | NCT02475213 |
PD-1 mAb (Nivolumab) | KIR (Lirilumab) | Solid Tumors | NCT01714739 |
PD-L1 mAb (MEDI4736) | OX40 (MEDI6383) | Solid Tumors | NCT02221960 |
PD-1 mAb (Nivolumab) | 4-1BB (Urelumab) | Solid tumors and B-cell non-Hodgkin lymphoma | NCT02253992 |
PD-1 mAb (Nivolumab) | ICOS (JTX-2011) | Solid Tumors | NCT02904226 |
Pd-1 mAb (PDR001) | GITR (GWN323) | Solid Tumors and Lymphomas | NCT02740270 |
PD-1 mAb (Nivolumab) | CD27 (Varlilumab) | Solid Tumors | NCT02335918 |
PD-L1 mAb (Atezolizumab) | CD27 (Varlilumab) | Solid Tumors | NCT02543645 |
PD-1 mAb (Nivolumab) | GM.CD40L (vaccine for NSCLC) | Lung (NSCLC) | NCT02466568 |
PD-L1 mAb (Atezolizumab) | VEGF inhibitors (Bevacizumab cediranib) | Ovarian Cancer | NCT02659384 |
PD-L1 mAb (MEDI4736) | PARP inhibitors (Olaparib) | S tumors | NCT02484404 |
PD-L1 mAb (MEDI4736) | Multi-kinase inhibitor (Sunitinib) | Solid tumors | NCT02484404 |
PD-1 mAb (Pembrolizumab) with SBRT | Multi-kinase inhibitor (Sunitinib) | TKI refractory mRCCa | NCT02599779 |
PD-L1 mAb (Durvalumab) | EGFR inhibitor (Osimertinib) | Lung (NSCLC) | reference [70] |